Press Release

<< Back
View printer-friendly version

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

PHILADELPHIA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 6, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the third quarter that ended Sept. 30, 2018, and recent business highlights.

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international) and entering passcode 2370749. To access a live audio webcast, please visit the “Investors” section of the Spark Therapeutics website at

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 2370749, or by visiting the “Investors” section of the Spark Therapeutics website at

About Spark Therapeutics
At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit, and follow us on Twitter and LinkedIn.

Investor Contact:                            
Ryan Asay                                 
(215) 239-6424  

Media Contact:
Monique da Silva
(215) 282-7470                                  

Spark Therapeutics Logo

Source: Spark Therapeutics, Inc.